Chemogenomic approaches to drug discovery.

[1]  C L Verlinde,et al.  Structure-based drug design: progress, results and challenges. , 1994, Structure.

[2]  R. Treisman,et al.  Regulation of transcription by MAP kinase cascades. , 1996, Current opinion in cell biology.

[3]  A. Abbott.  German physicians warn of genetics risks , 1996, Nature.

[4]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[5]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[6]  G. Bemis,et al.  The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. , 1997, Chemistry & biology.

[7]  J. Drews,et al.  Drug Development: The role of innovation in drug development , 1997, Nature Biotechnology.

[8]  Ajay,et al.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.

[9]  S. Schreiber.  Chemical genetics resulting from a passion for synthetic organic chemistry. , 1998, Bioorganic & medicinal chemistry.

[10]  B. Chait,et al.  The structure of the potassium channel: molecular basis of K+ conduction and selectivity. , 1998, Science.

[11]  Elizabeth J. Goldsmith,et al.  Acquisition of Sensitivity of Stress-activated Protein Kinases to the p38 Inhibitor, SB 203580, by Alteration of One or More Amino Acids within the ATP Binding Pocket* , 1998, The Journal of Biological Chemistry.

[12]  K. Wilson,et al.  A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase , 1998, Protein science : a publication of the Protein Society.

[13]  E. A. O'neill,et al.  Molecular basis for p38 protein kinase inhibitor specificity. , 1998, Biochemistry.

[14]  Mark A. Murcko,et al.  Virtual screening : an overview , 1998 .

[15]  C. Dinarello.  Interleukin‐1β, Interleukin‐18, and the Interleukin‐1β Converting Enzyme a , 1998 .

[16]  Philip R. Cohen,et al.  The development and therapeutic potential of protein kinase inhibitors. , 1999, Current opinion in chemical biology.

[17]  N. Marks,et al.  Recent advances on neuronal caspases in development and neurodegeneration , 1999, Neurochemistry International.

[18]  M. Lamers,et al.  Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. , 1999, Journal of molecular biology.

[19]  Ajay,et al.  Designing libraries with CNS activity. , 1999, Journal of medicinal chemistry.

[20]  G. Bemis,et al.  Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.

[21]  Ajay,et al.  The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.

[22]  M. Murcko,et al.  Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. , 1999, Journal of medicinal chemistry.

[23]  S. Frye.  Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. , 1999, Chemistry & biology.

[24]  P. Traxler,et al.  ATP site‐directed competitive and irreversible inhibitors of protein kinases , 2000, Medicinal research reviews.

[25]  J. D. Elliott,et al.  Drug discovery in the next millennium. , 2000, Annual review of pharmacology and toxicology.

[26]  K. Wilson,et al.  The structures of caspases-1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity. , 2000, Chemistry & biology.

[27]  Mark A. Murcko,et al.  Library Filtering Systems and Prediction of Drug‐Like Properties , 2000 .

[28]  C. Debouck,et al.  The impact of genomics on drug discovery. , 2000, Annual review of pharmacology and toxicology.

[29]  Forecasting roles of combinatorial chemistry in the age of genomically derived drug discovery targets. , 2000 .

[30]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[31]  L Hong,et al.  Crystal structure of an in vivo HIV‐1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance , 2000, Protein science : a publication of the Protein Society.

[32]  J. Louis,et al.  Structural implications of drug‐resistant mutants of HIV‐1 protease: High‐resolution crystal structures of the mutant protease/substrate analogue complexes , 2001, Proteins.

[33]  J. Peng,et al.  Nuclear magnetic resonance-based approaches for lead generation in drug discovery. , 2001, Methods in enzymology.

[34]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[35]  H. Robert Guy,et al.  The gating mechanism of the large mechanosensitive channel MscL , 2001, Nature.

[36]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[37]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.